Addex TherapeuticsADXN
13F holders, Q2 2025 (June 30)5holders
1new positions
1sold out
$9.19avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Addex Therapeutics Ltd. (ADXN) in their 13F filings, unchanged from Q1 2025. 1 opened new positions and 1 sold out. The largest holders were GAMMA Investing LLC ($1K), Morgan Stanley ($941) and JPMorgan Chase & Co. ($699).
- Company
- Addex Therapeutics Ltd.
- CUSIP
- 00654J206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $699 |
| Exits | 1 | $86K |
All 13F filers, Q1 2025 → Q2 2025: 79 shares bought and 12,813 shares sold, net −12,734 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| GAMMA Investing LLC | 0.00% | Reduce -89.9% | 121 | $1K |
| Morgan Stanley | 0.00% | No change | 100 | $941 |
| JPMorgan Chase & Co. | 0.00% | New | 79 | $699 |
| Rhumbline Advisers | 0.00% | No change | 72 | $637 |
| SBI Securities Co., Ltd. | 0.00% | No change | 5 | $47 |
"% of holder's portfolio" is ADXN's weight in each manager's 13F, not the share of Addex Therapeutics Ltd. the manager owns.